Apollo Endosurgery (APEN) and iRadimed Corporation (IRMD) Head-To-Head Survey
Apollo Endosurgery (NASDAQ: APEN) and iRadimed Corporation (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, profitability and earnings.
This is a breakdown of recent ratings and target prices for Apollo Endosurgery and iRadimed Corporation, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Apollo Endosurgery currently has a consensus price target of $11.00, indicating a potential upside of 147.19%. iRadimed Corporation has a consensus price target of $12.00, indicating a potential upside of 18.81%. Given Apollo Endosurgery’s higher probable upside, analysts clearly believe Apollo Endosurgery is more favorable than iRadimed Corporation.
Risk & Volatility
Apollo Endosurgery has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, iRadimed Corporation has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.
Institutional and Insider Ownership
8.9% of Apollo Endosurgery shares are owned by institutional investors. Comparatively, 14.2% of iRadimed Corporation shares are owned by institutional investors. 74.2% of Apollo Endosurgery shares are owned by insiders. Comparatively, 60.1% of iRadimed Corporation shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Apollo Endosurgery and iRadimed Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Apollo Endosurgery and iRadimed Corporation’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Apollo Endosurgery||$63.01 million||1.22||-$10.53 million||N/A||N/A|
|iRadimed Corporation||$24.35 million||4.39||$4.51 million||$0.24||42.09|
iRadimed Corporation has higher revenue, but lower earnings than Apollo Endosurgery.
iRadimed Corporation beats Apollo Endosurgery on 7 of the 11 factors compared between the two stocks.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company’s products include ORBERA, LAP-BAND and OverStitch. The Company’s product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.
iRadimed Corporation Company Profile
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
Receive News & Stock Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related stocks with our FREE daily email newsletter.